ArticleOncotarget2016

A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.

Lina Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.